Olivia M. T. Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivia M. T. Davies has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Dawn H. Siegel
Department of Dermatology Stanford University School of Medicine Palo Alto California USA
5 shared publications Beth A. Drolet
Department of Dermatology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
4 shared publicationsDawn H. Siegel
Departments of Dermatology and (by courtesy) Pediatrics Stanford University School of Medicine Palo Alto California USA
4 shared publicationsIlona J. Frieden
Department of Dermatology University of California‐San Francisco San Francisco California USA
4 shared publicationsMaria C. Garzon
Departments of Dermatology and Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York
3 shared publications- Beth A. Drolet
Department of Dermatology University of Wisconsin Madison Wisconsin USA
2 shared publications
Latest Publications
- 1 October 2024
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (10) , 714
Reactive Perforating Collagenosis: Answer
- 1 October 2024
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (10) , 714
Reactive Perforating Collagenosis: Answer
- 1 October 2024
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (10) , e87-e88
A Rash and Intractable Pruritus After Hemodialysis Initiation: Challenge
- 1 October 2024
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (10) , e87-e88
A Rash and Intractable Pruritus After Hemodialysis Initiation: Challenge
- Open Access
- 26 April 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (2) , 286-289
Expanding global health dermatology leadership: launching the GLODERM international mentorship programme
The lack of access to dermatological care is a global health crisis. Providing intentional mentorship to emerging leaders in low- and middle-income countries is foundational to increasing access to care. The GLODERM Mentorship Programme is a first-of-its-kind programme created to support changemakers in global health dermatology in enhancement of leadership skills.
- 26 April 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (2) , 286-289
Open AccessExpanding global health dermatology leadership: launching the GLODERM international mentorship programme
The lack of access to dermatological care is a global health crisis. Providing intentional mentorship to emerging leaders in low- and middle-income countries is foundational to increasing access to care. The GLODERM Mentorship Programme is a first-of-its-kind programme created to support changemakers in global health dermatology in enhancement of leadership skills.
- Open Access
- 14 June 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 789-808
Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines
Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide variety of indications since then. However, despite widespread off‐label use, FDA labeling does not include approved indications for the use of MTX for many inflammatory skin diseases in pediatric patients, including morphea, psoriasis, atopic dermatitis, and alopecia areata, among others. Without published treatment guidelines, some clinicians may be hesitant to use MTX off‐label, or uncomfortable prescribing MTX in this population. To address this unmet need, an expert consensus committee was convened to develop evidence‐ and consensus‐based guidelines for use of MTX to treat pediatric inflammatory skin disease. Clinicians with experience and expertise in clinical research, drug development, and treating inflammatory skin disease in pediatric patients with MTX were recruited. Five committees were created based on major topic areas: (1) indications and contraindications, (2) dosing, (3) interactions with immunizations and medications, (4) adverse effects (potential for and management of), and (5) monitoring needs. Pertinent questions were generated and addressed by the relevant committee. The entire group participated in a modified Delphi process to establish agreement on recommendations for each question. The committee developed 46 evidence‐ and consensus‐based recommendations, each with >70% agreement among members, across all five topics. These are presented in tables and text, along with a discussion of supporting literature, and level of evidence. These evidence‐ and consensus‐based recommendations will support safe and effective use of MTX for the underserved population of pediatric patients who may benefit from this valuable, time‐honored medication.
- 14 June 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 789-808
Open AccessMethotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines
Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide variety of indications since then. However, despite widespread off‐label use, FDA labeling does not include approved indications for the use of MTX for many inflammatory skin diseases in pediatric patients, including morphea, psoriasis, atopic dermatitis, and alopecia areata, among others. Without published treatment guidelines, some clinicians may be hesitant to use MTX off‐label, or uncomfortable prescribing MTX in this population. To address this unmet need, an expert consensus committee was convened to develop evidence‐ and consensus‐based guidelines for use of MTX to treat pediatric inflammatory skin disease. Clinicians with experience and expertise in clinical research, drug development, and treating inflammatory skin disease in pediatric patients with MTX were recruited. Five committees were created based on major topic areas: (1) indications and contraindications, (2) dosing, (3) interactions with immunizations and medications, (4) adverse effects (potential for and management of), and (5) monitoring needs. Pertinent questions were generated and addressed by the relevant committee. The entire group participated in a modified Delphi process to establish agreement on recommendations for each question. The committee developed 46 evidence‐ and consensus‐based recommendations, each with >70% agreement among members, across all five topics. These are presented in tables and text, along with a discussion of supporting literature, and level of evidence. These evidence‐ and consensus‐based recommendations will support safe and effective use of MTX for the underserved population of pediatric patients who may benefit from this valuable, time‐honored medication.
- 29 March 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 367-368
A 12‐year‐old male with localized, pink, tender papules
- 29 March 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 367-368
A 12‐year‐old male with localized, pink, tender papules
- Open Access
- 22 December 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 1042-1051.e3
PTPN11 Mosaicism Causes a Spectrum of Pigmentary and Vascular Neurocutaneous Disorders and Predisposes to Melanoma
- 22 December 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 1042-1051.e3
Open AccessPTPN11 Mosaicism Causes a Spectrum of Pigmentary and Vascular Neurocutaneous Disorders and Predisposes to Melanoma
- Open Access
- 10 August 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (6) , 914-919
Early‐onset hypertension associated with extensive cutaneous capillary malformations harboring postzygotic variants in GNAQ and GNA11
Background and Objectives: Cutaneous capillary malformations (CMs) describe a group of vascular birthmarks with heterogeneous presentations. CMs may present as an isolated finding or with other associations, including glaucoma and leptomeningeal angiomatosis (i.e., Sturge–Weber syndrome) or pigmentary birthmarks (i.e., phakomatosis pigmentovascularis). The use of targeted genetic sequencing has revealed that postzygotic somatic variations in GNAQ and GNA11 at codon 183 are associated with CMs. We report five patients with early‐onset hypertension and discuss possible pathogenesis of hypertension.Methods: Twenty‐nine patients with CMs, confirmed GNAQ/11 postzygotic variants, and documented past medical history were identified from a multi‐institutional vascular anomalies study. Early‐onset hypertension was defined as hypertension before the age of 55 years. Clinical data were reviewed for evidence of hypertension, such as documentation of diagnosis or elevated blood pressure measurements.Results: Five of the 29 patients identified as having GNAQ/11 postzygotic variants had documented early‐onset hypertension. Three individuals harbored a GNAQ p.R183Q variant, and two individuals harbored a GNA11 p.R183C variant. All individuals had extensive cutaneous CMs involving the trunk and covering 9%–56% of their body surface area. The median age of hypertension diagnosis was 15 years (range 11–24 years), with three individuals having renal abnormalities on imaging.Conclusions: Early‐onset hypertension is associated with extensive CMs harboring somatic variations in GNAQ/11. Here, we expand on the GNAQ/11 phenotype and hypothesize potential mechanisms driving hypertension. We recommend serial blood pressure measurements in patients with extensive CMs on the trunk and extremities to screen for early‐onset hypertension.
- 10 August 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (6) , 914-919
Open AccessEarly‐onset hypertension associated with extensive cutaneous capillary malformations harboring postzygotic variants in GNAQ and GNA11
Background and Objectives: Cutaneous capillary malformations (CMs) describe a group of vascular birthmarks with heterogeneous presentations. CMs may present as an isolated finding or with other associations, including glaucoma and leptomeningeal angiomatosis (i.e., Sturge–Weber syndrome) or pigmentary birthmarks (i.e., phakomatosis pigmentovascularis). The use of targeted genetic sequencing has revealed that postzygotic somatic variations in GNAQ and GNA11 at codon 183 are associated with CMs. We report five patients with early‐onset hypertension and discuss possible pathogenesis of hypertension.Methods: Twenty‐nine patients with CMs, confirmed GNAQ/11 postzygotic variants, and documented past medical history were identified from a multi‐institutional vascular anomalies study. Early‐onset hypertension was defined as hypertension before the age of 55 years. Clinical data were reviewed for evidence of hypertension, such as documentation of diagnosis or elevated blood pressure measurements.Results: Five of the 29 patients identified as having GNAQ/11 postzygotic variants had documented early‐onset hypertension. Three individuals harbored a GNAQ p.R183Q variant, and two individuals harbored a GNA11 p.R183C variant. All individuals had extensive cutaneous CMs involving the trunk and covering 9%–56% of their body surface area. The median age of hypertension diagnosis was 15 years (range 11–24 years), with three individuals having renal abnormalities on imaging.Conclusions: Early‐onset hypertension is associated with extensive CMs harboring somatic variations in GNAQ/11. Here, we expand on the GNAQ/11 phenotype and hypothesize potential mechanisms driving hypertension. We recommend serial blood pressure measurements in patients with extensive CMs on the trunk and extremities to screen for early‐onset hypertension.
- 28 April 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (17) , 1587-1589
Needlestick
Already uncertain that she deserves to be in medical school, a medical student is thrown into despair when she accidentally sticks herself with a needle in the operating room in this Graphic Perspective.
- 28 April 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (17) , 1587-1589
Needlestick
Already uncertain that she deserves to be in medical school, a medical student is thrown into despair when she accidentally sticks herself with a needle in the operating room in this Graphic Perspective.
- 6 March 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (5) , e29639
Cutaneous mosaic RASopathies associated with rhabdomyosarcoma
Variants in RAS are known drivers of certain pediatric blood and solid cancers, including brain tumors. Though most RAS‐driven cancers are thought to occur sporadically, genetic syndromes caused by germline RAS variants portend a slightly higher risk of rhabdomyosarcoma (RMS) development. Three new cases and a review of the literature demonstrate that in rare cases, certain somatic RAS variants are associated with an increased risk of RMS and that RMS development may be heralded by the presence of concomitant RAS‐driven birthmarks. Further prospective studies are needed to establish incidence and recommend appropriate monitoring guidelines for patients at risk.
- 6 March 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (5) , e29639
Cutaneous mosaic RASopathies associated with rhabdomyosarcoma
Variants in RAS are known drivers of certain pediatric blood and solid cancers, including brain tumors. Though most RAS‐driven cancers are thought to occur sporadically, genetic syndromes caused by germline RAS variants portend a slightly higher risk of rhabdomyosarcoma (RMS) development. Three new cases and a review of the literature demonstrate that in rare cases, certain somatic RAS variants are associated with an increased risk of RMS and that RMS development may be heralded by the presence of concomitant RAS‐driven birthmarks. Further prospective studies are needed to establish incidence and recommend appropriate monitoring guidelines for patients at risk.